A family of structurally related but genetically distinct natriuretic peptides exist which include atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) of myocardial cell origin and C-type natriuretic peptide (CNP) of endothelial and renal epithelial cell origin. All three exert actions via cGMP, with ANP and BNP functioning via the natriuretic peptide A receptor and CNP via the natriuretic peptide B receptor.
INTRODUCTION
The natriuretic peptide system has emerged as a functionally important endocrine system of cardiovascular retic peptide (BNP) of myocardial cell origin and C-type natriuretic peptide (CNP) of endothelial and renal epithelial cell origin [5, 6] . This family of structurally similar but genetically distinct peptides possesses natriuretic, diuretic, renin-inhibiting and vasodilatory properties. These biological actions are mediated by the generation of the second messenger guanosine 3h :5h-cyclic monophosphate (cGMP) after peptide binding to their respective particulate guanylate cyclase receptors. ANP and BNP bind to the natriuretic peptide A receptor (NPR-A) while CNP binds to the natriuretic peptide B receptor (NPR-B). These receptors have been localized to kidney, vasculature and heart [7] .
Acute intravascular volume overload (AVO) is a physiological manoeuvre which, like acute heart failure, rapidly increases cardiac filling pressures and circulating ANP with resulting natriuresis [8, 9] . The integrated cardiorenal and endocrine response is a mechanism by which optimal body fluid and arterial pressure homoeostasis are maintained during alterations in cardiac filling pressures. Repeated studies have established that circulating ANP plays a role in the natriuretic response to acute AVO [8] [9] [10] [11] . Zhang and co-workers demonstrated that the natriuretic response to AVO in normal rats is attenuated by a specific antagonist to both NPR-A and NPR-B (HS-142-1) via attenuation of increases in glomerular filtration rate and decreases in tubular reabsorption [12, 13] . More recently the natriuretic response to acute volume expansion was abolished in mice in which NPR-A was absent [14] . While these recent studies provided insight into ANP during AVO, the physiological response of BNP and CNP during AVO remains poorly defined. Indeed, in vivo and in vitro studies conflict with regard to the increase in plasma BNP in response to acute cardiac overload [15] [16] [17] . Furthermore, the response of circulating and urinary CNP during AVO also remains poorly defined. The importance of elucidating the response of CNP to AVO is based upon its endothelial localization which may result in an enhanced sensitization to increases in shear stress ; an alternative mechanism may be as a result of enhanced CNP production in the kidney [6, 18, 19] . Additionally the participation of the natriuretic peptide system in the natriuretic response to AVO in the dog compared with the rat or mouse is undefined.
The current study was therefore designed to : (1) define circulating ANP, BNP and CNP and their relationships to cardiac filling pressures during AVO ; (2) define urinary ANP, BNP and CNP excretion during AVO ; and (3) define the role of the natriuretic peptide system in the natriuretic response to AVO in the normal anaesthetized dog, utilizing a natriuretic peptide receptor antagonist to both NPR-A and NPR-B (HS-142-1) [20] [21] [22] [23] . The renal specificity of HS-142-1 in the natriuretic response to AVO was also defined using frusemide at the conclusion of the protocol.
METHODS

Surgical preparation
Studies were performed in two groups (control group, n l 5 ; HS-142-1 group, n l 9) of pentobarbital-anaesthetized male mongrel dogs (18-20 kg) . The night before the experiment, all dogs received lithium carbonate (300 mg orally) and were then fasted but allowed free access to water. On the day of the experiment, the dogs were anaesthetized with intravenous pentobarbital (30 mg\kg) with supplemental doses administered as needed. The trachea was intubated using a 9.5 mm endotracheal tube and mechanically ventilated via a Harvard respirator with supplemental oxygen administered at a rate of 4 litres\min. The femoral artery was cannulated for measurement of systemic arterial pressure and for blood sampling. Both femoral veins were cannulated ; one venous catheter was used for infusion of inulin in saline at a rate of 1 ml\min and the second catheter was used for the saline AVO infusion. The right internal jugular vein was isolated and a 7 French balloontipped thermodilution pulmonary artery catheter (American Edwards Laboratory, Anasco, PR, U.S.A.) was advanced into the pulmonary artery. A left flank incision was made exposing the left kidney and the exposed ureter was cannulated with polyethylene tubing for urine collection. The renal artery was isolated in situ and an electromagnetic flow probe was placed on the renal artery and connected to a flow meter (Carolina Instruments, King, NC, U.S.A.).
Experimental protocol
After preparation, the dog was suspended in a prone position and allowed to stabilize for 1 h. A baseline period was obtained by a 15-min clearance performed before volume expansion. After completion of the baseline period, the study group received intravenous HS-142-1 at a dose of 3 mg\kg, and the control group received an equal volume of saline. This dose was based upon the ability of this concentration to attenuate the actions of endogenous and exogenous ANP in previous studies [22, 24] . To define the physiological actions of HS-142-1 alone, cardiovascular, renal and humoral measurements were obtained in four of the treated animals 5 min after administration of HS-142-1.
AVO was accomplished by infusion of normal saline equal to 10 % of body weight over 1 h. The volume expansion was controlled by a Harvard peristaltic pump (model 1201). Ten-minute clearances were obtained at 20, 40 and 60 min to determine the effect of 3.3 % (VE1), 6.6 % (VE2) and 10 % (VE3) acute volume overload. At 60 min, the rate of saline infusion was adjusted to equal the peak urine flow rate (single kidney flow rate times two). Saline was infused at this rate for 30 min and a final 10-min stable volume expansion (SVE) clearance was started at 90 min (SVE). After completion of the stable volume expansion, both groups received an intravenous bolus of 100 mg of frusemide infused over 2 min. A final 10-min clearance (FUR) was started 5 min after the frusemide was given.
During each clearance period, the following haemodynamic data were collected : mean arterial pressure (MAP), right atrial pressure (RAP), pulmonary artery pressure (PAP), pulmonary capillary wedge pressure (PCWP), renal blood flow (RBF) and cardiac output (CO). Cardiac output was measured by thermodilution (American Edwards Cardiac Output Computer model 9510-A). For each clearance, CO was measured in triplicate and then averaged. Systemic vascular resistance (SVR) was calculated as follows : SVR (dyne:
Analysis
Arterial blood was collected during each clearance period for analysis of ANP, BNP, CNP, plasma renin activity, cGMP, electrolytes and haematocrit. Plasma and urine ANP were measured by a specific RIA [25] . Blood for hormone analysis was collected in an EDTA tube and immediately placed on ice. After centrifugation at 2500 r.p.m. at 4 mC, plasma was separated and stored at k20 mC until assay. ANP was extracted by use of C") Bond Elut with a recovery of 86 %. ANP was measured by a RIA using a specific antibody to human ANP. Inter-assay variation was 9 %, intra-assay variation was 6 %, and cross-reactivity was 100 % with canine ANP. Crossreactivity to BNP or CNP was less than 0.1 %.
Plasma and urine BNP were determined by a specific RIA to canine BNP. One millilitre of plasma was preacidified and extracted on C-8 Bond Elut cartridge and eluted with 1 % trifluoroacetic acid\85 % methanol. Concentrated eluates were then assayed using a specific canine BNP antibody. Samples or standards were incubated for 18 h at 4 mC with 100 µl of antibody. Onehundred microlitres of I"#&-labelled BNP was added and incubated for another 18 h at 4 mC. Free and bound fractions were then separated by the addition of a second antibody and centrifugation, and the pellet was counted. Minimum detectable concentration for the assay is 0.5 pg\tube. Recovery for this assay is 75p11 %, interand intra-assay variability was 12 % and 10 % respectively. The cross-reactivity of the BNP assay to other structurally related peptides was determined by the addition of synthetic ANP-28 and CNP-22 (Phoenix Pharmaceuticals, Mountain View, CA, U.S.A.) in concentrations ranging from 0.5 to 500 pg\tube. Cross-reactivity to ANP or CNP was less than 0.1 %.
Plasma and urine CNP were also determined by a specific RIA [6] . Samples were extracted by the Vycor glass technique modified from the method of Gutkowska et al. [26] . Briefly, 1 ml of plasma or urine was gently mixed with 0.5 ml of Vycor glass suspension for 1 h at 4 mC. The Vycor was washed with water and the CNP was eluted from the Vycor with 60 % acetone in 0.5 M HCl. Eluates were concentrated on a Savant, and pellets were resuspended in assay buffer for RIA. CNP immunoreactivity was then determined using a specific antibody to CNP-22 (Phoenix Pharmaceuticals). Recovery of CNP was 72p6 % as determined by addition of synthetic CNP to plasma. The lower limit of detection was 2 pg\tube. Intra-assay variability is 5.2 %. Cross-reactivity of the CNP-22 antibody with CNP-53 was established by the addition of synthetic CNP-53 to the CNP-22 assay at concentrations ranging from 2 to 500 pg. The cross-reactivity was 87p6 %. There was no reported cross-reactivity between the specific CNP-22 antibody and ANP or BNP. This was verified by the addition of synthetic ANP and BNP (Phoenix Pharmaceuticals) to CNP at concentrations ranging from 0.5 to 500 pg with no detectable immunoreactivity.
Plasma and urinary cGMP were measured by RIA using the method of Steiner et al. [27] . Glomerular filtration rate was determined by the clearance of inulin. Plasma and urine inulin concentrations were measured by the anthrone method [28] . Urinary and plasma lithium levels were determined by flame emission spectrophotometry (model 357, Instrumentation Laboratory, Wilmington, MA, U.S.A.). Lithium clearances were used as an indirect method to calculate distal fractional tubular reabsorption : [(clearance of lithiumkclearance of sodium)\clearance of lithium]i100 [29, 30] . Plasma and urine electrolytes including lithium were measured by flame-emission spectrophotometry (IL943 Flame Photometer, Instrumentation Laboratory, Lexington, MA, U.S.A.).
Data from the clearance periods (baseline, VE1, VE2, VE3, SVE and FUR) were expressed as meanspS.E.M. Data were assessed by Student's unpaired t-test and factorial analysis of variance for comparisons between groups, Student's paired t-tests for single comparisons of absolute changes within each group, and by analysis of variance for repeated measures followed by Bonferroni post test when appropriate. Statistical significance was accepted as P 0.05.
RESULTS
Cardiac filling pressures, plasma and urinary natriuretic peptides during AVO
In both groups, PCWP and right atrial pressure (RAP) increased during AVO. Circulating ANP increased at peak AVO paralleling changes in cardiac filling pressures. In contrast, neither plasma BNP nor plasma CNP increased in response to AVO (Figure 1 ). Statistical significance : *P 0.05 compared with baseline.
Compared with baseline, urinary ANP and BNP excretion did not increase during AVO. However, urinary CNP excretion was increased in both groups at peak AVO. There was no difference in urinary ANP, BNP or CNP between control and HS-142-1-treated groups and these are thus summarized together ( Figure  2 ).
Cardiovascular, endocrine and renal responses to AVO in the presence and absence of HS-142-1
Cardiovascular responses (Table 1) In the absence of HS-142-1, AVO resulted in increases in MAP, CO and PAP. SVR tended to decrease. Left (PCWP) and right atrial pressures increased during AVO. In the HS-142-1 group AVO resulted in similar increases in MAP, CO, RAP, PCWP and PAP and decreases in Plasma and urinary natriuretic peptides during volume overload SVR. There was no significant change observed in MAP in the HS-142-1-treated group compared with controls.
Endocrine responses (Table 2) In the control group, AVO increased plasma ANP with no changes in plasma BNP or CNP. Plasma cGMP increased by period VE2 and remained elevated throughout the study protocol.
Similar to the control group, AVO in the HS-142-1-treated group resulted in increases in circulating ANP with no changes in plasma BNP or CNP. In contrast to the control group, HS-142-1 prevented the increase in circulating cGMP in response to AVO. Plasma cGMP concentrations in the HS-142-1 group were decreased compared with the control group at VE2, VE3, SVE and FUR. Renal responses (Table 3) AVO resulted in no changes in glomerular filtration rate, RBF or RVR in the control group. Both urine flow and urine sodium excretion were increased in response to AVO. Fractional excretion of sodium was increased at VE2, VE3, SVE and FUR compared with baseline. Distal fractional tubular reabsorption of sodium was decreased at VE3, SVE and FUR. Urinary cGMP excretion did not significantly change from baseline values.
There were no differences in glomerular filtration rate, RBF or RVR between the control and HS-142-1-treated group. Intravenous administration of HS-142-1 markedly attenuated the natriuretic and diuretic response to AVO compared with the control group. Both urinary sodium excretion (VE1, VE2, VE3 and SVE) and fractional sodium excretion (VE1, VE2 and VE3) were markedly attenuated in the HS-142-1-treated group (Figure 3) . Urine flow was attenuated at VE1, VE2, VE3 and SVE in the HS-142-1 group compared with the control group. Frusemide administration after stable volume expansion resulted in a similar brisk natriuresis and diuresis in both groups. Similar decreases in proximal tubular reabsorption of sodium were observed in both groups during AVO. Distal tubular reabsorption of sodium tended to be greater in the HS-142-1 group, reaching significance during VE3. Urinary cGMP excretion was decreased at VE1 and VE2 in the HS-142-1-treated group.
Cardiorenal and endocrine responses to HS-142-1 before AVO
Acute administration of HS-142-1 before AVO resulted in no changes in MAP, CO, RAP, PAP, PCWP or SVR. Circulating ANP, BNP and CNP remained unchanged while cGMP decreased. No changes were observed in glomerular filtration rate, RBF or tubular reabsorption of sodium after HS-142-1 administration.
DISCUSSION
The present study provides new insight into the natriuretic peptide system in the integrated cardiorenalendocrine responses to AVO. These studies demonstrate that circulating ANP and not BNP or CNP is the humoral marker for acute increases in cardiac filling pressures during AVO. Secondly, urinary CNP which is selectively enhanced serves as a urinary marker for AVO. These studies confirm and extend previous reports and demonstrate that pharmacological inhibition of both particulate guanylate cyclase receptors markedly attenuates the natriuretic response to AVO but not to frusemide. Based upon these findings, the current investigation establishes that the natriuretic peptide system participates in the natriuretic responses to acute AVO and that the circulating and urinary natriuretic peptides are differentially regulated during this physiological stimulus.
Repeated investigations have established that atrial stretch secondary to increases in atrial pressures serves as the principal stimulus for ANP release from the heart [10, 17, 31] . Thus, the parallel increase in plasma ANP and cardiac filling pressures in the current study during AVO confirms previous investigations. To date, however, the associated responses of circulating BNP and CNP to AVO remain poorly defined. Of importance is the recent report that BNP synthesis by cultured ventricular myocytes is more rapid compared with ANP in response to humoral stimulation [17] . Indeed, these investigators speculated that BNP may function as the emergency natriuretic peptide during acute cardiac overload. Therefore, the current findings of the lack of change in circulating BNP extend previous reports and demonstrate differential control of plasma ANP and BNP during acute AVO. This lack of change in circulating BNP during AVO is further evidence for differential synthesis and release mechanisms for BNP compared with ANP [32] . Additionally, the selective increase in ANP and not BNP supports a more primary role for ANP in the acute regulation of cardiorenal function compared with BNP. Thus, plasma ANP rather than BNP serves as the circulating marker for acute changes in cardiac filling pressure. The current observation is con-sistent with the report of Wambach and Koch [16] demonstrating the lack of increase in plasma BNP during saline volume expansion in normal humans. The lack of change in CNP during AVO suggests that CNP may function more as a paracrine and autocrine factor and not as a circulating hormone, as recent studies demonstrate no elevation of plasma CNP in human heart failure compared with increases in myocardial tissue CNP [33] .
Several studies have advanced a key role for ANP as a mediator of the natriuretic and diuretic responses to AVO based upon an attenuation in natriuresis and diuresis with administration of ANP antibodies, surgical removal of the atrial appendages, or knockout of NPR-A [9, 14, 20] . HS-142-1 is a non-peptide antagonist isolated from the fungus culture broth of Aureobasidium sp. which selectively inhibits both the natriuretic peptide A and B particulate guanylate cyclase receptors in vivo and in vitro [20] [21] [22] [23] . Studies have established that HS-142-1 inhibits natriuretic peptide binding to rabbit cortical membranes without blocking or binding to angiotensin or endothelin. In vascular smooth muscle HS-142-1 selectively abolishes the activation of cGMP mediated by the natriuretic peptides but not by sodium nitroprusside [34] . Previous studies from this and other laboratories demonstrate that HS-142-1 selectively attenuates the natriuresis and diuresis induced by ANP in both anaesthetized rats and dogs [12, 13, 24, 35] . Intravenous administration of HS-142-1 had no effect upon cardiorenal haemodynamics or sodium excretion at baseline. In contrast, the decrease in tubular sodium reabsorption and resulting natriuresis during AVO were markedly attenuated by HS-142-1. This specific blockade appears to be at the tubular level as the attenuated renal natriuretic response was not associated with an alteration in glomerular filtration rate or RBF compared with the control group. The selective action of this antagonist was demonstrated by the marked natriuretic response to frusemide in the presence of the receptor antagonist. Thus, as plasma ANP and urinary CNP increased during AVO, the current findings and previous studies suggest a role for the natriuretic peptide system in the natriuretic response to AVO.
The physiological response of circulating and urinary CNP to acute AVO has not been previously reported. CNP has been shown to preferentially relax isolated veins compared with arteries [36] , and its natriuretic effects remain controversial. Indeed, we and others have reported that CNP administration in dogs does not increase urinary sodium excretion. Nonetheless, CNP is mildly natriuretic in the rat. Furthermore, NPR-B is present in the kidney and its gene expression is increased in the kidney in response to decreases in dietary sodium [37, 38] . Additional indirect evidence for a possible renal role for CNP is the report that CNP inhibits angiotensinconverting enzyme and the generation of angiotensin II [39] . The increase in urinary CNP excretion during AVO suggests a further potential role for CNP as a paracrine factor in the renal regulation of the natriuretic and diuretic response to AVO. The mechanism for the increase in urinary CNP remains unclear, but it is tempting to speculate that the known increase in renal interstitial pressure which occurs during AVO could serve as a mechanical stimulus for CNP release by renal epithelial cells [40] . Further studies are warranted to investigate the potential renal role of CNP in AVO. A limitation of the current study is that the control group exists without a comparison to a time control group. Nonetheless, the cardiorenal and endocrine responses observed in the control group are similar to those reported in previous studies in both animals and humans [8, 13, 16] .
In conclusion, the present study demonstrates the differential release of myocardial and renal natriuretic peptides in acute AVO. During AVO, plasma ANP serves as the selective marker for acute changes in cardiac filling pressures while urinary CNP serves as a marker for increases in intravascular and possibly renal interstitial pressures. Neither plasma nor renal BNP increased in response to AVO. Treatment with HS-142-1 markedly attenuated AVO-mediated natriuresis and diuresis, underscoring the functional physiological role of the natriuretic peptide system in mediating the natriuretic response to AVO. Therefore these studies support a role for circulating ANP but not BNP as a rapidly released cardiac hormone, and urinary CNP as a renally generated natriuretic peptide in response to AVO. These two peptides may thus play an integral role in the maintenance of sodium and water balance resulting in the preservation of cardiorenal homoeostasis during acute saline volume overload.
